DK3484514T3 - Compositions and methods related to engineered fc constructs - Google Patents

Compositions and methods related to engineered fc constructs Download PDF

Info

Publication number
DK3484514T3
DK3484514T3 DK17803463.3T DK17803463T DK3484514T3 DK 3484514 T3 DK3484514 T3 DK 3484514T3 DK 17803463 T DK17803463 T DK 17803463T DK 3484514 T3 DK3484514 T3 DK 3484514T3
Authority
DK
Denmark
Prior art keywords
engineered
constructs
compositions
methods related
methods
Prior art date
Application number
DK17803463.3T
Other languages
English (en)
Inventor
Carlos J Bosques
Jonathan C Lansing
Nathanial J Washburn
Daniel Ortiz
Laura Rutitzky
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3484514T3 publication Critical patent/DK3484514T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17803463.3T 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs DK3484514T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US201762443451P 2017-01-06 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Publications (1)

Publication Number Publication Date
DK3484514T3 true DK3484514T3 (da) 2024-01-29

Family

ID=60412547

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17803463.3T DK3484514T3 (da) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Country Status (14)

Country Link
US (4) US11155640B2 (da)
EP (2) EP3464376A4 (da)
JP (4) JP2019519527A (da)
KR (3) KR102635635B1 (da)
CN (4) CN109789203B (da)
AU (2) AU2017272109A1 (da)
BR (2) BR112018074032A2 (da)
CA (2) CA3025306A1 (da)
DK (1) DK3484514T3 (da)
ES (1) ES2973251T3 (da)
IL (3) IL309293A (da)
PL (1) PL3484514T3 (da)
SG (3) SG11201810465RA (da)
WO (2) WO2017205436A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016024780A2 (pt) 2014-05-02 2017-10-10 Momenta Pharmaceutical Inc composições e métodos relacionados com construtos de fc manipulados
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US11220531B2 (en) 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs
BR112021000391A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4
AU2019300020A1 (en) * 2018-07-11 2021-02-18 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs
WO2020014505A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
MX2021000305A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
WO2020014526A2 (en) * 2018-07-11 2020-01-16 Anthony Manning Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
EP3820521A4 (en) * 2018-07-11 2022-04-13 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING ANTI-CTLA-4 DOMAIN CONSTRUCTS
EP3820998A4 (en) * 2018-07-11 2022-04-27 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING ANTI-PD-L1 DOMAIN CONSTRUCTS
JP2021531268A (ja) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド 改変されたFc抗原結合ドメイン構築体に関する組成物および方法
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
KR20220062084A (ko) 2019-09-13 2022-05-13 체에스엘 베링 렝나우 아게 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체
AU2020394844A1 (en) 2019-12-06 2022-06-30 CSL Behring Lengnau AG Stable compositions of Fc multimers
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
US20220177549A1 (en) * 2020-12-07 2022-06-09 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2000515731A (ja) 1996-06-14 2000-11-28 スミスクライン・ビーチャム・コーポレイション 6量体融合タンパク質およびその使用
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU784285B2 (en) 1999-12-24 2006-03-02 Genentech Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
CA2667678A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
ES2565834T3 (es) 2007-06-01 2016-04-07 University Of Maryland, Baltimore Agentes de unión a receptor de Fc de región constante de inmunoglobulina
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
PL2247304T3 (pl) 2008-04-02 2017-01-31 Macrogenics, Inc. Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
CA2747011C (en) 2008-12-18 2018-06-19 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2010135534A2 (en) 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
CA2766065C (en) * 2009-06-30 2020-07-21 Research Development Foundation Immunoglobulin fc polypeptides
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
RU2583298C2 (ru) 2009-10-07 2016-05-10 Макродженикс, Инк. ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
BR112012029611A2 (pt) * 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
PL2654780T3 (pl) * 2010-12-23 2017-07-31 Janssen Biotech, Inc Aktywne mutanty przeciwciała fc odporne na proteazy
EP2686348B1 (en) 2011-03-17 2015-12-30 Ramot at Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
SG10201602371VA (en) 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. プロコアグラント化合物
CA2877363A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
EP2885320A4 (en) 2012-08-20 2016-04-06 Gliknik Inc MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY
US20150218236A1 (en) 2012-10-17 2015-08-06 Liverpool School Of Tropical Medicine Immunomodulatory proteins
CN104558194B (zh) 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
EP3082847A1 (en) 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
EP3094649A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding properties
EP3835318A1 (en) 2014-01-15 2021-06-16 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
EP3114137A1 (en) 2014-03-05 2017-01-11 UCB Biopharma SPRL Multimeric fc proteins
JP6851200B2 (ja) 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル 多量体Fcタンパク質
BR112016024780A2 (pt) * 2014-05-02 2017-10-10 Momenta Pharmaceutical Inc composições e métodos relacionados com construtos de fc manipulados
TWI707872B (zh) 2014-05-29 2020-10-21 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
US20220153833A1 (en) 2016-03-02 2022-05-19 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US11220531B2 (en) * 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs

Also Published As

Publication number Publication date
BR112018074056A2 (pt) 2019-03-06
IL263213B2 (en) 2024-05-01
KR20190026684A (ko) 2019-03-13
AU2017272109A1 (en) 2019-01-17
US20240067757A1 (en) 2024-02-29
KR102590061B1 (ko) 2023-10-18
JP2019519528A (ja) 2019-07-11
KR102462084B1 (ko) 2022-11-02
EP3484514B1 (en) 2023-12-06
CN109789203A (zh) 2019-05-21
JP7045333B6 (ja) 2022-05-06
EP3464376A4 (en) 2020-03-18
US20220049019A1 (en) 2022-02-17
JP2019519527A (ja) 2019-07-11
BR112018074032A2 (pt) 2019-02-26
IL263211A (en) 2018-12-31
US20190284305A1 (en) 2019-09-19
KR102635635B1 (ko) 2024-02-14
KR20190021255A (ko) 2019-03-05
US11155640B2 (en) 2021-10-26
CN109963869A (zh) 2019-07-02
AU2017272111A1 (en) 2019-01-17
WO2017205434A1 (en) 2017-11-30
JP2022095685A (ja) 2022-06-28
EP3484514A4 (en) 2020-08-12
CN118206639A (zh) 2024-06-18
EP3484514A1 (en) 2019-05-22
PL3484514T3 (pl) 2024-04-29
SG11201810466PA (en) 2018-12-28
IL263211B2 (en) 2023-09-01
IL309293A (en) 2024-02-01
KR20220151025A (ko) 2022-11-11
CA3025306A1 (en) 2017-11-30
JP7045333B2 (ja) 2022-03-31
US11623964B2 (en) 2023-04-11
JP2022068176A (ja) 2022-05-09
CA3025310A1 (en) 2017-11-30
AU2017272111B2 (en) 2024-05-16
EP3464376A1 (en) 2019-04-10
SG11201810465RA (en) 2018-12-28
ES2973251T3 (es) 2024-06-19
SG10202011624SA (en) 2021-01-28
CN116063540A (zh) 2023-05-05
WO2017205436A1 (en) 2017-11-30
IL263213A (en) 2018-12-31
IL263213B1 (en) 2024-01-01
US20210221917A1 (en) 2021-07-22
JP7295301B2 (ja) 2023-06-20
CN109789203B (zh) 2022-08-05
IL263211B1 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
IL286367A (en) Compositions and methods relating to engineered fc constructs
DK3484514T3 (da) Compositions and methods related to engineered fc constructs
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
BR112017000039A2 (pt) composições agrícolas e aplicações que utilizam óleos essenciais
DK3221363T3 (da) Antistoffer mod cd73 og anvendelser deraf
DK3169741T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3116533T3 (da) Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
KR20180084891A (ko) 구조 조성물 및 방법
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
EP3423572A4 (en) METHODS RELATING TO MANIPULATED FC CONSTRUCTS
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
BR112016024191A2 (pt) composições e aplicações agrícolas utilizando compostos minerais
DK3183295T3 (da) Fraktioneret alkyleret cyclodextrinsammensætning og fremgangsmåder til fremstilling og anvendelse af samme
SG10202107391YA (en) Compositions and methods related to engineered fc constructs
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
BR112017012240A2 (pt) métodos de preparação de composições contendo alcaloides e suas utilizações
DK3113774T3 (da) Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf
DK3233104T3 (da) Immunterapi-behandlinger og -sammensætninger
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
DK3099314T3 (da) Tolerogene sammensætninger og anvendelser deraf
KR20180084930A (ko) 접착제 조성물 및 구조체
FR3026639B1 (fr) Composition cosmetique